Regeneron (REGN) said Saturday that Libtayo reduced the risk of recurrence or death by 68% in post-surgical high-risk cutaneous squamous cell carcinoma, meeting the phase 3 C-POST trial's primary endpoint.
The immunotherapy also cut the risk of locoregional and distant recurrence by 80% and 65%, respectively, the company said.
Median disease-free survival was not reached in the Libtayo group versus 49 months for placebo, with two-year disease-free survival rates of 87% and 64%, respectively, Regeneron said.
The company said adverse events of grade 3 or higher occurred in 24% of Libtayo patients versus 14% for placebo, treatment discontinuation due to adverse events was 10% in the Libtayo arm.
Regulatory applications for adjuvant use of Libtayo have been submitted in the US and EU, Regeneron added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.